AU2012350437B2 - Medical composition for preventing or treating amyloid beta peptide related diseases or conditions - Google Patents

Medical composition for preventing or treating amyloid beta peptide related diseases or conditions Download PDF

Info

Publication number
AU2012350437B2
AU2012350437B2 AU2012350437A AU2012350437A AU2012350437B2 AU 2012350437 B2 AU2012350437 B2 AU 2012350437B2 AU 2012350437 A AU2012350437 A AU 2012350437A AU 2012350437 A AU2012350437 A AU 2012350437A AU 2012350437 B2 AU2012350437 B2 AU 2012350437B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
polar solvent
isoacteoside
acteoside
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012350437A
Other languages
English (en)
Other versions
AU2012350437A1 (en
Inventor
Young-Ming Huang
Hang-Ching Lin
Muh-Hwan Su
Jing-jing TANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sinphar Tian Li Pharmaceutical Co Ltd
Original Assignee
Sinphar Tian Li Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinphar Tian Li Pharmaceutical Co Ltd filed Critical Sinphar Tian Li Pharmaceutical Co Ltd
Publication of AU2012350437A1 publication Critical patent/AU2012350437A1/en
Application granted granted Critical
Publication of AU2012350437B2 publication Critical patent/AU2012350437B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G4/00—Chewing gum
    • A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
    • A23G4/10—Chewing gum characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/64—Orobanchaceae (Broom-rape family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012350437A 2011-12-16 2012-12-17 Medical composition for preventing or treating amyloid beta peptide related diseases or conditions Active AU2012350437B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161576367P 2011-12-16 2011-12-16
US61/576,367 2011-12-16
PCT/CN2012/086796 WO2013087042A1 (zh) 2011-12-16 2012-12-17 预防或治疗淀粉样β肽相关疾病或状况的医药组合物

Publications (2)

Publication Number Publication Date
AU2012350437A1 AU2012350437A1 (en) 2014-07-31
AU2012350437B2 true AU2012350437B2 (en) 2017-06-29

Family

ID=48580733

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012350437A Active AU2012350437B2 (en) 2011-12-16 2012-12-17 Medical composition for preventing or treating amyloid beta peptide related diseases or conditions

Country Status (11)

Country Link
US (1) US20150087606A1 (https=)
EP (1) EP2792361B1 (https=)
JP (1) JP6134331B2 (https=)
KR (1) KR102048289B1 (https=)
CN (1) CN103156867B (https=)
AU (1) AU2012350437B2 (https=)
CA (1) CA2859227C (https=)
MY (1) MY171048A (https=)
SG (1) SG11201403265VA (https=)
TW (1) TWI488630B (https=)
WO (1) WO2013087042A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150291645A1 (en) * 2014-04-10 2015-10-15 Sinphar Pharmaceutical Co., Ltd. Isoacteoside derivative and use thereof
TWI650131B (zh) * 2014-07-03 2019-02-11 杏輝藥品工業股份有限公司 管花肉蓯蓉萃取物之用於製備保護眼部細胞之藥品或食品用途
CN104922137B (zh) * 2015-06-04 2018-07-31 苏州大学 苯乙醇苷类化合物Torenoside B的新用途
KR102018085B1 (ko) * 2017-12-06 2019-09-04 김좌진 악테오사이드를 함유하는 뇌종양 치료 및 전이 억제용 약학 조성물
KR102135148B1 (ko) * 2019-08-28 2020-07-20 김좌진 악테오사이드를 함유하는 뇌종양 치료 및 전이 억제용 약학 조성물
CN110812375A (zh) * 2019-12-12 2020-02-21 中国海洋大学 一种老鼠簕中苯乙醇苷类提取物及其制备方法与作为抗肝损伤药物的应用
CN111632058A (zh) * 2020-06-24 2020-09-08 新疆医科大学 毛蕊花糖苷在制备预防和治疗神经退行性疾病药物中的应用
CN112225766A (zh) * 2020-10-27 2021-01-15 杏辉天力（杭州）药业有限公司 一种由肉苁蓉萃取物中富集及分离苯乙醇苷类化合物的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040162246A1 (en) * 2003-02-18 2004-08-19 Sinphar Pharmaceutical Co., Ltd. Medicinal preparation containing phenylethanoid glycosides extracted from herbaceous plant, cistanche tubulosa (schenk.) wight, process of making the same, and uses of the same
JP2009196905A (ja) * 2008-02-19 2009-09-03 Univ Kinki カンカニクジュヨウから得られる肝保護剤及び抗ＴＮＦ−α作用剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100500584B1 (ko) * 2002-08-12 2005-07-12 경희대학교 산학협력단 신경성장인자와 유사 작용을 갖는 육종용 추출물 및 이를함유하는 조성물
KR100514076B1 (ko) * 2003-01-10 2005-09-13 주식회사 엘컴사이언스 페닐에타노이드 유도체를 포함하는 퇴행성 뇌신경계질환의 예방 및 치료용 조성물
CN1268341C (zh) * 2003-03-04 2006-08-09 杏辉天力（杭州）药业有限公司 来源于管花肉苁蓉的含有苯乙醇苷的制剂及其制备方法和用途
CN100345857C (zh) * 2004-07-16 2007-10-31 北京华医神农医药科技有限公司 一种从肉苁蓉药材中提取、分离松果菊苷的方法
EP1736167B1 (en) * 2005-06-20 2018-03-21 I.R.B. Istituto Di Ricerche Biotecnologiche S.r.l. Extracts obtained from cell line cultures from Syringa vulgaris IRB-SV25/B (DMS:16857), their preparation and use
CN101411753B (zh) * 2008-12-04 2012-02-29 闫明 列当总苷在制备抗老年痴呆的药物中的应用
CN101797307B (zh) * 2010-04-09 2011-08-10 广州中医药大学 一种含苯乙醇苷的枇杷叶紫珠提取物及其制备方法
TWI486162B (zh) * 2010-06-16 2015-06-01 Sinphar Pharmaceutical Co Ltd 異類葉升麻苷或其醫藥學上可接受之鹽於抑制澱粉樣β肽生成、累積或聚集、以及製備預防或治療澱粉樣β肽相關疾病或狀況的藥物之用途
CN102670631B (zh) * 2011-12-01 2013-07-31 河南科技大学 一种四楞麻总苯乙醇苷组合物、制备方法及应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040162246A1 (en) * 2003-02-18 2004-08-19 Sinphar Pharmaceutical Co., Ltd. Medicinal preparation containing phenylethanoid glycosides extracted from herbaceous plant, cistanche tubulosa (schenk.) wight, process of making the same, and uses of the same
JP2009196905A (ja) * 2008-02-19 2009-09-03 Univ Kinki カンカニクジュヨウから得られる肝保護剤及び抗ＴＮＦ−α作用剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LU & SHEN: "Water-soluble Constituents from Callicarpa pedunculata" Chinese Journal of Natural Medicine, 2008, vol. 6, no. 3, pp. 176-178 *

Also Published As

Publication number Publication date
MY171048A (en) 2019-09-23
TW201325597A (zh) 2013-07-01
WO2013087042A1 (zh) 2013-06-20
SG11201403265VA (en) 2014-09-26
KR102048289B1 (ko) 2020-01-08
EP2792361A1 (en) 2014-10-22
JP2015500300A (ja) 2015-01-05
TWI488630B (zh) 2015-06-21
CA2859227A1 (en) 2013-06-20
US20150087606A1 (en) 2015-03-26
EP2792361B1 (en) 2019-03-27
CN103156867A (zh) 2013-06-19
CA2859227C (en) 2019-01-22
JP6134331B2 (ja) 2017-05-24
KR20150002576A (ko) 2015-01-07
AU2012350437A1 (en) 2014-07-31
EP2792361A4 (en) 2015-05-13
CN103156867B (zh) 2019-04-30

Similar Documents

Publication Publication Date Title
AU2012350437B2 (en) Medical composition for preventing or treating amyloid beta peptide related diseases or conditions
Tian et al. The anti-aging mechanism of ginsenosides with medicine and food homology
JP5969738B2 (ja) 抗糖化作用剤
CN102743402B (zh) 人参二醇皂苷组分在制备防治皮炎和疤痕药物中的用途
KR20210096701A (ko) 뼈 장애, 연골 장애, 또는 이 둘 다의 관리 또는 개선을 위한 조성물 및 방법
CN106967147B (zh) C27螺甾烷型甾体皂苷化合物与其药物组合物和其应用
Lin et al. Novel lactulose and melibiose targeting autophagy to reduce polyQ aggregation in cell models of spinocerebellar ataxia 3
JP7577351B2 (ja) 新規エラジタンニンおよび口腔用剤
CN104382980A (zh) 一种具有延缓衰老的星油藤茎叶提取物及其制备和应用
Araújo et al. Neuropharmacological characterization of frutalin in mice: Evidence of an antidepressant-like effect mediated by the NMDA receptor/NO/cGMP pathway
Dong et al. Pharmacological effect of panax notoginseng saponins on cerebral ischemia in animal models
JP4994222B2 (ja) 血小板凝集抑制剤
CN101050226A (zh) 一种牡荆素衍生物分离方法
ES2743716T3 (es) Derivado de hidroximetilfurfural
KR101628853B1 (ko) 자가면역 질환을 치료하기 위한 조성물 및 방법
EP3666269A1 (en) Blood flow improver
JP2013241356A (ja) Ｔｉｅ２活性化剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤、並びに医薬品組成物
JP2005023000A (ja) 抗菌剤及びその製造方法、並びに食品製剤及び消毒剤
Choi et al. Differential effects of the steaming time and frequency for manufactured red Liriope platyphylla on nerve growth factor secretion ability, nerve growth factor receptor signaling pathway and regulation of calcium concentration
JP5992661B2 (ja) ヒアルロン酸産生促進剤
KR101349361B1 (ko) 등골나물 추출물의 근위축 예방, 치료 또는 개선을 위한 용도
KR20150068865A (ko) 진세노사이드 Rg3를 유효성분으로 포함하는 노화세포 회춘용 조성물
Fu et al. Protective effect of ginsenoside Rh3 on myocardial ischemia-reperfusion injury in rats by regulation of p38 MAPK/caspase-3 signaling pathway
Yang et al. Enhancement of neutral endopeptidase activity in SK-N-SH cells by ginsenoside Rb1
KR101946282B1 (ko) 생약 성분을 포함하는 유방암 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)